The analysis revealed that renal cancer patients with elevated ISOC1 expression demonstrated enhanced sensitivity to Sorafenib, Afuresertib, Dabrafenib, Nilotinib and Sabutoclax. This evidence concerns the gene ISOC1 and renal carcinoma.